Abstract
Biologic therapy of cancer can be defined as a treatment that acts primarily through defense mechanisms or by the administration of natural mammalian substances. Two important questions emerge when considering using the body’s immune defenses to treat cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Rosenberg, S.A., J.C. Yang, S.L. Topalian, D.J. Schwartzentruber, J.S. Weber, D.R. Parkinson, CA. Seipp, J.H. Einhorn, and D.E. White. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907.
Muul, L.M. 1987. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J.Immunol 755:989.
Rosenberg, S.A. 1990. Adoptive immunotherapy for cancer. Sci.Am. 262:62.
Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, K. Sakaguchi, E. Appella, J.R. Yannelli, G.J. Adema, T. Miki, and S.A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc.Natl.AcadSci.U.S.A. 91:6458.
Rosenberg, S.A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol.Today 18:175.
Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, L. Rivoltini, S.L. Topalian, T. Miki, and S.A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc.Natl.Acad.SciU.S.A. 91
Rosenberg, S.A. and D.E. White. 1996. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J.Immunother.Emphasis. Tumor Immunol. 79:81.
Overwijk, W.W., D.S. Lee, D.R. Surman, K.R. Irvine, C.E. Touloukian, C.C. Chan, M.W. Carroll, B. Moss, S.A. Rosenberg, and N.P. Restifo. 1999. Vaccination with a recombinant vaccinia virus encoding a “self antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes. Proc.Natl.AcadSci.U.S.A. 96:2982.
Boon, T., P.G. Coulie, and D.E. Van. 1997. Tumor antigens recognized by T cells. Immunol.Today 18:261.
Rosenberg, S.A. 1999. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 10:281.
Tsang, K.Y., S. Zaremba, CA. Nieroda, M.Z. Zhu, J.M. Hamilton, and J. Schlom. 1995. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J.Natl.Cancer Inst. 87:982.
Jager, E., Y.T. Chen, J.W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand H. Wada, Y. Noguchi, E. Stockert, L.J. Old, and A. Knuth. 1998. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J.Exp.Med. 187:265
Robbins, P.F., M. el-Gamil, Y.F. Li, Y. Kawakami, D. Loftus, E. Appella, and S.A. Rosenberg. 1996. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J.Exp.Med. 183:1185.
Morin, P.J., A.B. Sparks, V. Korinek, N. Barker, H. Clevers, B. Vogelstein, and K.W. Kinzler. 1997. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787.
Rubinfeld, B., P. Robbins, M. ei-Gamil, I. Albert, E. Porfiri, and P. Polakis. 1997. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275:1790.
Overwijk, W.W., A. Tsung, K.R. Irvine, M.R. Parkhurst, T.J. Goletz, K. Tsung, M.W. Carroll, C. Liu, B. Moss, S.A. Rosenberg, and N.P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J.Exp.Med 188:211.
Parkhurst, M.R., M.L. Salgaller, S. Southwood, P.F. Robbins, A. Sette, S.A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J.Immunol. 757:2539.
Cormier, J.N., M.L. Salgaller, T. Prevette, K.C. Barracchini, L. Rivoltini, N.P. Restifo, S.A. Rosenberg, and F.M. Marincola. 1997. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J.Sci.Am. 5:37.
Salgaller, M.L., F.M. Marincola, J.N. Cormier, and S.A. Rosenberg. 1996. Immunization against epitopes in the human melanoma antigen gp 100 following patient immunization with synthetic peptides. Cancer Res. 56:4149.
Rosenberg, S.A., J.C. Yang, D.J. Schwartzentruber, P. Hwu, F. Marincola, S.L. Topalian, N.P. Restifo, M.E. Dudley, S.L. Schwarz, P.J. Spiess, J.R. Wunderlich, M.R. Parkhurst, Y. Kawakami, C.A. Seipp, J.H. Einhorn, and D.E. White. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat.Med. 4:321.
Rosenberg, S.A., Y. Zhai, J.C. Yang, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, S.L. Topalian, N.P. Restifo, C.A. Seipp, J.H. Einhorn, B. Roberts, and D.E. White. 1998. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp 100 melanoma antigens. J.Natl. Cancer Inst. 90
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Overwijk, W.W., Rosenberg, S.A. (2000). 200 Years after Jenner: The Search for a Cancer Vaccine. In: Goldstein, A.L. (eds) Frontiers in Biomedicine. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4217-9_22
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4217-9_22
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6893-9
Online ISBN: 978-1-4615-4217-9
eBook Packages: Springer Book Archive